LBEPB17	Analytical treatment interruption among African women and Peruvian men & transgender individuals with early ART initiation +/- VRC01 circulating at HIV acquisition: early observations of viral rebound & control	E-poster	Other strategies and therapies
LBEPB18	Anti-PD-L1 antibody ASC22 in combination with chidamide potentiates HIV latency reversal and immune function from ART-suppressed individuals: a single center, single-arm, phase 2 study	E-poster	Other strategies and therapies
LBEPB20	T-cell responses induced by HTI vaccines and vesatolimod correlate with improved control of HIV rebound	E-poster	Other strategies and therapies
TUPEB15	Ruxolitinib-mediated HIV-1 reservoir decay in A5336 phase 2a trial	Poster exhibition	Other strategies and therapies
TUPEB16	Transformation of 3 current short-acting HIV drugs, tenofovir, lamivudine and dolutegravir (TLD) into a novel, all-in-one long-acting TLD 3-drug-combination in a single injectable dosage that produces extended pharmacokinetics	Poster exhibition	Other strategies and therapies
TUPEB17	A biodegradable, subcutaneous implant delivery platform to treat HIV for up to 6 months in young children	Poster exhibition	Other strategies and therapies
EPA0083	Engineering macaque B cells for persistent anti-HIV broadly neutralizing antibodies production	E-poster	Novel treatment and prevention strategies
EPA0084	(5R)-5-Hydroxytriptolide inhibits immune activation in SIV-infected ART-treated rhesus macaques	E-poster	Novel treatment and prevention strategies
EPA0085	Dual therapy of Interleukin-21 and anti-α4β7 antibody administration during ART-treated SIV promotes immunological responses and ameliorates dysbiosis in rhesus macaques	E-poster	Novel treatment and prevention strategies
EPA0086	Claisened Hexafluoro treatment ameliorates cognitive deficits in HIV associated neurocognitive disorders (HAND) mice and improves the underlying brain pathogenicity	E-poster	Novel treatment and prevention strategies